TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024
April 10, 2024 03:00 ET
|
TILT Biotherapeutics Oy
HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and...
TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research
February 14, 2024 03:00 ET
|
TILT Biotherapeutics Oy
HELSINKI, Finland, Feb. 14, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces it has been selected by the U.S....
TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint Resistant Metastatic Melanoma Phase I Trial at ESMO Immuno-Oncology 2023
December 08, 2023 03:00 ET
|
TILT Biotherapeutics Oy
HELSINKI, Finland, Dec. 08, 2023 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company at the forefront of developing cancer immunotherapies, presented safety and...
TILT Biotherapeutics Announces Positive Clinical Data on Lead Asset TILT-123 at Society for Immunotherapy of Cancer 2023
November 06, 2023 03:00 ET
|
TILT Biotherapeutics Oy
HELSINKI, Finland, Nov. 06, 2023 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company at the forefront of developing cancer immunotherapies, presented Phase I data...
TILT Biotherapeutics Announces First Patient Dosed in Phase I Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination with Checkpoint Inhibitor
May 15, 2023 02:00 ET
|
TILT Biotherapeutics Oy
HELSINKI, Finland, May 15, 2023 (GLOBE NEWSWIRE) -- TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the first patient has been...